| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 | 2025-089 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于不向下修正"华海转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 8 月 15 日，浙江华海药业股份有限公司（以下简称"公司"） 股价已出现任意三十个连续交易日中至少十五个交易日收盘价格低于当期转股 价格 80%的情形，触及"华海转债"转股价格向下修正条款。 经公司第九届董事会第三次临时会议审议通过，公司董事会决议本次不行使 "华海转债"转股价格向下修正的权利，且在未来 2 个月内（2025 年 8 月 16 日 至 2025 年 10 月 15 日），如再次触及可转债的转股价格向下修正条款，亦不提出 向下修正方案。从 2025 年 10 月 16 日开始重新起算，若再次触发"华海转债" 转股价格向下修正 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2025-088 号 浙江华海药业股份有限公司 第九届董事会第三次临时会议决议公告 一、审议通过了《关于不向下修正"华海转债"转股价格的议案》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 具体内容详见公司于 2025 年 8 月 16 日刊登在中国证券报、上海证券报、证券 时报、证券日报及上海证券交易所网站（www.sse.com.cn）上的《浙江华海药业股 份有限公司关于不向下修正"华海转债"转股价格的公告》。 特此公告。 浙江华海药业股份有限公司 董事会 二零二五年八月十五日 1 / 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第三次临时会议于 二零二五年八月十五日下午十五点以通讯方式在公司四楼会议室召开。会议应到会 董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 长李宏先生主持。会议程序符合《公司法》及《公司章程》的规 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has established a new subsidiary, Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd., with an investment of 400 million RMB, focusing on research and experimental development in the pharmaceutical industry [1] Company Summary - Huahai Tianheng (Shanghai) Pharmaceutical Research Co., Ltd. was founded on September 23, 2024, with a registered capital of 400 million RMB and is wholly owned by Zhejiang Huahai Pharmaceutical Co., Ltd. [1] - The company is located in Shanghai and is involved in various activities including medical research and experimental development, import and export of goods and technology, data processing and storage support services, and various technical services [1] - The company is authorized to engage in several licensed activities such as drug production, wholesale, retail, import and export, contract manufacturing, and clinical trial services, subject to regulatory approvals [1] Industry Summary - The establishment of Huahai Tianheng indicates a strategic move within the pharmaceutical industry, emphasizing the importance of research and development in enhancing the company's capabilities and market position [1]

Core Viewpoint - The article discusses the approval and details of the Guangdong Province Synthetic Biology Manufacturing Pilot Platform Project, highlighting its investment, construction scale, and the upcoming SynBioCon 2025 conference focused on synthetic biology and green manufacturing trends [3][4][5]. Project Approval and Details - The Guangdong Provincial Development and Reform Commission approved the preliminary design budget for the Synthetic Biology Manufacturing Pilot Platform Project, with a total investment of 21,733,000 yuan, including engineering costs of 19,459,000 yuan and other expenses [3]. - The project will establish four major pilot platforms: an intelligent microbial pilot platform, a functional macromolecule pilot platform, a green biomass methanol pilot platform, and an intelligent plant pilot platform, covering a construction area of approximately 8,500 square meters and acquiring about 365 sets of instruments and equipment [3][4]. SynBioCon 2025 Conference - The SynBioCon 2025 conference will be held from August 20 to 22 in Ningbo, Zhejiang, focusing on four main areas: AI in biological manufacturing, green chemical engineering and new materials, future food, and future agriculture [5]. - The conference aims to explore the development trends of the biological manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the continuous vitality brought by new technologies and products [5]. - Various activities will take place during the conference, including a youth forum, high-level discussions, and a closed-door seminar on the "2025 Blue Book for AI Empowering Biological Manufacturing Industry Innovation" [5][11].

Group 1 - The company, Zhejiang Huahai Pharmaceutical Co., Ltd., has issued convertible bonds with a total amount of 1,842.60 million bonds, each with a face value of 100.00 yuan, totaling 184,260.00 million yuan [3] - The convertible bond, referred to as "Huahai Convertible Bond," is listed on the Shanghai Stock Exchange with the code "110076" and has a maturity period of six years from the issuance date [3] - The conversion price for the bonds is set at 33.06 yuan per share, with the conversion period running from May 6, 2021, to November 1, 2026 [2] Group 2 - The company anticipates that the conditions for a downward adjustment of the conversion price may be triggered, as the stock price has been below 80% of the current conversion price for 10 trading days within a 30-day period [6] - If the downward adjustment condition is triggered, the company will convene a board meeting to decide whether to adjust the conversion price and will disclose the decision in a timely manner [6][5] - The adjustment process requires a two-thirds majority approval from shareholders present at the meeting, excluding those holding the convertible bonds [4] Group 3 - The company has previously announced on April 26, 2025, that it would not adjust the conversion price of the "Huahai Convertible Bond" [6] - The company is obligated to disclose any decisions regarding the adjustment of the conversion price in accordance with the regulations set by the Shanghai Stock Exchange [6][5] - Investors can refer to the prospectus published on October 29, 2020, for more information regarding the "Huahai Convertible Bond" [7]

| | | 浙江华海药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 关于"华海转债"预计触发转股价格向下修正的提示性公告 ●根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 规定，"上市公司应当在预计触发转股价格修正条件的 5 个交易日前及时披露提示 性公告。"自 2025 年 7 月 26 日至 2025 年 8 月 8 日，公司股票在连续 30 个交易日 中已有 10 个交易日的收盘价低于当期转股价格的 80%，预计触发转股价格向下修 正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股价 格，并及时履行信息披露义务。 一、可转债上市发行概况 根据中国证券监督管理委员会《关于核准浙江华海药业股份有限公司公开发行 可转换公司债券的批复》（证监许可[2020]2261 号），公司于 2020 年 11 月 2 日公 开发行了 1,842.60 万张可转换公司债券（以下简称"可转债"），每张面值 100.00 元，发行总额 184,260.00 万 ...

沪指8月7日上涨0.16%，申万所属行业中，今日上涨的有18个，涨幅居前的行业为有色金属、美容护 理，涨幅分别为1.20%、0.99%。跌幅居前的行业为医药生物、电力设备，跌幅分别为0.92%、0.74%。 医药生物行业位居今日跌幅榜首位。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688166 | 博瑞医药 | -5.70 | 3.89 | 23275.85 | | 002173 | 创新医疗 | 10.01 | 30.10 | 22618.18 | | 000710 | 贝瑞基因 | 5.26 | 23.64 | 20015.67 | | 300289 | 利德曼 | 20.02 | 21.71 | 17141.65 | | 002022 | 科华生物 | 9.96 | 12.63 | 15290.70 | | 300981 | 中红医疗 | 19.99 | 8.06 | 11833.89 | | 300760 | 迈瑞医疗 | 1.09 | 0.60 | 11395.45 | | 00 ...

截至8月7日收盘，创新药概念下跌1.41%，位居概念板块跌幅榜前列，板块内，千红制药跌停，华海药 业、亚太药业、康弘药业等跌幅居前，股价上涨的有36只，涨幅居前的有润都股份、海辰药业、粤万年 青等，分别上涨9.98%、7.22%、6.19%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 稀土永磁 | 3.24 | 减肥药 | -1.70 | | 脑机接口 | 2.69 | CRO概念 | -1.66 | | 高压氧舱 | 2.56 | 创新药 | -1.41 | | 太赫兹 | 1.65 | 仿制药一致性评价 | -1.34 | | 血氧仪 | 1.62 | 重组蛋白 | -1.29 | | 存储芯片 | 1.40 | 中船系 | -1.28 | | MCU芯片 | 1.18 | 阿尔茨海默概念 | -1.18 | | 无线耳机 | 1.08 | 特钢概念 | -1.02 | | 汽车芯片 | 1.02 | 细胞免疫治疗 | -1.02 | | DRG/DIP | 1.00 | PET铜箔 | -0.99 ...

截至8月7日收盘，仿制药一致性评价概念下跌1.34%，位居概念板块跌幅榜前列，板块内，千红制药跌 停，华海药业、亚太药业、联环药业等跌幅居前，股价上涨的有18只，涨幅居前的有润都股份、海辰药 业、*ST苏吴等，分别上涨9.98%、7.22%、4.63%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 稀土永磁 | 3.24 | 减肥药 | -1.70 | | 脑机接口 | 2.69 | CRO概念 | -1.66 | | 高压氧舱 | 2.56 | 创新药 | -1.41 | | 太赫兹 | 1.65 | 仿制药一致性评价 | -1.34 | | 血氧仪 | 1.62 | 重组蛋白 | -1.29 | | 存储芯片 | 1.40 | 中船系 | -1.28 | | MCU芯片 | 1.18 | 阿尔茨海默概念 | -1.18 | | 无线耳机 | 1.08 | 特钢概念 | -1.02 | | 汽车芯片 | 1.02 | 细胞免疫治疗 | -1.02 | | DRG/DIP | 1.00 | PET铜箔 | ...

Core Viewpoint - The article discusses the significant price disparity of prescription drugs in the U.S. compared to other developed countries, leading to new policies aimed at price control and the potential impact on multinational pharmaceutical companies and emerging markets [1][2]. Group 1: U.S. Drug Pricing Policies - U.S. prescription drug prices are 2-3 times higher than those in other developed countries, with some innovative drugs priced at 10 times higher than in China [1] - New policies require pharmaceutical companies to provide "most favored nation pricing" to U.S. Medicare, sign contracts for price locking, renegotiate overseas prices to "repatriate profits," and promote direct sales for price transparency [1][2] - The Pharmaceutical Research and Manufacturers of America (PhRMA) criticized these policies, claiming they would undermine U.S. innovation [1][2] Group 2: Multinational Pharmaceutical Companies' Strategies - Companies like Johnson & Johnson, Pfizer, and Merck are adopting multi-faceted strategies to balance profits and compliance, including adjusting global pricing strategies [3] - Some companies are lowering prices in the U.S. while increasing prices in other markets to maintain profit margins, with AstraZeneca already announcing price reductions for certain drugs in the U.S. [3][4] - To offset profit losses, companies may raise prices in emerging markets like China, where the annual treatment cost for PD-1 drugs is approximately 1.16 million yuan, ten times higher than in China [4] Group 3: Cost Optimization Strategies - Cost reduction is a core objective, leveraging China's low-cost advantages, where biopharmaceutical R&D costs are 1/5 to 1/10 of those in the U.S. [5] - Pfizer has signed over $1 billion in CDMO orders with Chinese companies to transfer some biopharmaceutical production to China, reducing production costs by 30% [5][6] - Companies are also transferring non-core technologies to China to avoid tariffs and lower costs, such as Pfizer's collaboration with Chinese firms to establish PD-1 production bases [6][7] Group 4: Legal and Policy Maneuvering - Industry associations and pharmaceutical companies are using legal and political avenues to resist new policies, with PhRMA planning to appeal to the WTO regarding the "most favored nation pricing" requirement [10] - They are lobbying Congress, arguing that foreign price controls could reduce U.S. R&D investment by $10 billion annually [10] Group 5: Opportunities and Challenges for Chinese Companies - Chinese companies are positioned to benefit from accelerated domestic substitution, with local biosimilars gaining price advantages [11] - CDMO businesses are expanding, with WuXi Biologics reporting a 144% year-on-year increase in CDMO revenue in the first half of 2025 [12] - Chinese pharmaceutical companies are also achieving breakthroughs in international markets through licensing agreements, with total upfront payments reaching $2.329 billion in the first half of 2025 [13] Group 6: Beneficiary Companies - Companies in the biosimilar sector, such as Innovent Biologics and Antengene, are expected to gain market share as multinational firms raise prices in China [16] - WuXi Biologics is recognized as a leading global CDMO, while other companies like Eastone and Hengrui are also expanding their CDMO projects [17] - Chinese firms that have established production facilities in India and Southeast Asia, like Huahai Pharmaceutical, are likely to benefit from reduced reliance on the U.S. market [19]